Remove In-Vitro Remove Manufacturing Remove Research
article thumbnail

CDSCO releases draft guidance document on stability studies of IVD Medical Devices

AuroBlog - Aurous Healthcare Clinical Trials blog

The Central Drugs Standard Control Organisation (CDSCO) has released a draft guidance document on stability studies of In-vitro Diagnostic Medical Device (IVDMD) to aid manufacturers in the preparation of premarket review documents for the import or manufacturing license applications.

In-Vitro 241
article thumbnail

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

Devex’s global COVID-19 funding dashboard recorded $172 million invested in vaccine research between 1 January 2020 and 27 June 2020. Research into the therapeutic use of mRNA had been ongoing for decades prior to the COVID-19 pandemic. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Should IVD Manufacturers Look for When Selecting a Lab Testing Partner?

XTalks

In vitro diagnostics, or IVD, is a field where precision, reliability and robust partnerships propel advancement. The collaboration between IVD manufacturers and lab testing partners is central to precise and efficient diagnostic processes. But why should IVD manufacturers choose Quest Diagnostics as one of these partners?

article thumbnail

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.

DNA 130
article thumbnail

Top 30 New Medical Devices of 2024

XTalks

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

article thumbnail

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. Betta will be responsible for the development, manufacture and commercialisation of CFT8919 in the licensed territories.

In-Vivo 130
article thumbnail

Pfizer Responds to Research Claims

Pfizer

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. and around the world.

Research 112